Pulmonary Arterial Hypertension Formulary Central

Accessing Pulmonary Arterial Hypertension (PAH) Medication - It Takes a Village!

Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs among Patients with Pulmonary Arterial Hypertension in a Real-World US Database

Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy

Healthcare Resource Utilization and Costs for Patients with Pulmonary Arterial Hypertension: Real-world Documentation of Functional Class

Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database

Combination Therapy in Pulmonary Arterial Hypertension (PAH): What We Know and What We Do Not Know

Baseline Demographics and Clinical Characteristics of Chronic Thromboembolic Pulmonary Hypertension Patients in the US Medicare Population

Multiparameter Risk Assessment Tools Applied to the Functional Class (FC II) Cohort from the EARLY (AC-052364) Clinical Trial

Comparative Effectiveness of Oral Prostacyclin Pathway Medications on Hospitalization Among Patients with PH: A Retrospective Administrative Claims Study in a US Managed Care Population

Healthcare Costs and Resource Utilization Prior to Initiation of a Prostacylcin Receptor Agonist for Pulmonary Arterial Hypertension in a Real-world Database Representing a Large US Health Plan

Characterizing Patients Treated with Macitentan for Pulmonary Arterial Hypertension (PAH) in the US Opsumit User Registry (OPUS)

Treatment Patterns Prior to Initiation of a Prostacyclin Receptor Agonist for Pulmonary Arterial Hypertension in a Real-world Database Representing a Large US Health Plan

Medication Adherence and Risk of Hospitalization in Pulmonary Arterial Hypertension (PAH) Patients Treated with Endothelin Receptor Antagonists (ERAS) or Phosphodiesterase Type 5 Inhibitors (PDE-5IS)

Medication Adherence and Risk of Hospitalization in Pulmonary Arterial Hypertension (PAH) Patients Treated with Endothelin Receptor Antagonists (ERAS) or Phosphodiesterase Type 5 Inhibitors (PDE5IS)

Healthcare Utilization and Costs in Pulmonary Arterial Hypertension (PAH) Patients Treated with Endothelin Receptor Antagonists (ERAS) or Phosphodiesterase Type 5 Inhibitors (PDE-5Is)

Treatment Patterns and Medication Adherence and Persistence Among Patients with Pulmonary Arterial Hypertension in a Real-World Database Representing a Large US Health Plan

Comparing PAH-related Hospitalizations Between Hypothetical Commercial and Medicare Patients Using a Decision Tree Model

Decreasing Length of Stay and Pulmonary Arterial Hypertension Related Hospitalizations with Macitentan Using a Decision Tree Model in a Medicare Population

Characteristics of Patients Treated for Pulmonary Arterial Hypertension in a Real-World Database Representing a Large US Health Plan

Reducing Pulmonary Arterial Hypertension-Related Hospitalizations and Length of Stay with Macitentan Using a Decision Tree Model

Supplement | Considerations for Optimal Management of Patients With Pulmonary Arterial Hypertension: A Multi-Stakeholder Roundtable Discussion

Supplement | The Evolution of Prostacyclins in Pulmonary Arterial Hypertension: From Classical Treatment to Modern Management

Supplement | Characterizing Pulmonary Hypertension–Related Hospitalization Costs Among Medicare Advantage or Commercially Insured Patients With Pulmonary Arterial Hypertension: A Retrospective Database Study

Supplement | Combination Therapy in Pulmonary Arterial Hypertension: Is This the New Standard of Care?

Supplement | Pulmonary Arterial Hypertension: Progress and Challenges in the Modern Treatment Era

Supplement | Clinical Trial Designs in PAH: Shifting From Functional Measurements to Long-term Clinical Outcomes

Characteristics of Patients, Treatment Patterns and Medication Adherence and Persistence among Patients with Pulmonary Arterial Hypertension in a Large US Health Plan

Pulmonary Arterial Hypertension (PAH) Episodes of Care: Survival Analysis of PAH Patients Based on World Health Organization (WHO) Functional Class (FC)

Minimizing Burden of Disease-Related Hospitalization Among Pulmonary Arterial Hypertension Patients

Treatment Patterns Among Patients Prescribed Pde-5 Inhibitor Monotherapy For Pulmonary Arterial Hypertension

The Patterns of Healthcare Utilization and Prevalence of Pulmonary Arterial Hypertension Patients on Prostacyclin Therapy in the United States

Characteristics of Patients Treated for Pulmonary Arterial Hypertension in a Real-World Database Representing a Large US Health Plan

This page is brought to you by